Insulet Corporation (NASDAQ:PODD) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Insulet Corporation (NASDAQ:PODD) have received a consensus recommendation of “Moderate Buy” from the twenty-eight brokerages that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and twenty-two have given a buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $238.6667.

A number of analysts have weighed in on the company. William Blair assumed coverage on Insulet in a research report on Wednesday, May 20th. They set an “outperform” rating for the company. Wall Street Zen cut Insulet from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Stifel Nicolaus decreased their price objective on Insulet from $350.00 to $250.00 in a research report on Thursday, May 7th. TD Cowen reduced their price target on Insulet from $379.00 to $294.00 and set a “hold” rating for the company in a report on Monday, June 1st. Finally, Raymond James Financial set a $216.00 price target on Insulet in a research note on Monday, June 8th.

Insulet Stock Performance

NASDAQ:PODD opened at $158.25 on Monday. The stock’s 50 day moving average price is $159.09 and its 200 day moving average price is $220.11. The company has a market capitalization of $10.96 billion, a PE ratio of 36.80, a P/E/G ratio of 1.10 and a beta of 1.13. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. Insulet has a 52-week low of $138.79 and a 52-week high of $354.88.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same period last year, the firm earned $1.02 EPS. The firm’s revenue for the quarter was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, research analysts anticipate that Insulet will post 6.46 EPS for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the firm’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.36% of the stock is currently owned by company insiders.

Institutional Trading of Insulet

A number of institutional investors have recently modified their holdings of the business. State Street Corp boosted its stake in shares of Insulet by 2.1% in the fourth quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock valued at $896,916,000 after buying an additional 65,317 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Insulet by 2.1% in the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after buying an additional 41,019 shares in the last quarter. Invesco Ltd. boosted its stake in shares of Insulet by 10.5% in the fourth quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock valued at $420,835,000 after buying an additional 141,167 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its holdings in Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after purchasing an additional 1,011,369 shares during the last quarter. Finally, Norges Bank purchased a new stake in Insulet during the fourth quarter worth $300,794,000.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.